GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy?
After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE: LLY) announced ...
Fierce Healthcare15h
Primary care doctors concerned about telehealth GLP-1 boom: survey
As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...
Medscape23h
GLP-1 Reduces Recurrent Ischemic Stroke in Type 2 Diabetes
Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...
WHYY20h
After success with weight loss GLP-1 drugs, IBX patients face high costs after insurer drops coverage for obesity
Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.
Medscape15h
GLP-1 Therapies for HFpEF: Optimizing Outcomes Through Patient-Centered Care
Dr Pandey shares key insights on dosing, monitoring, and patient education to sustain therapy and improve outcomes. Essential for cardiologists and PCPs!
All-you-can’t-eat: GLP-1 drugs pose new challenges for restaurants, but how do they work?
When Trova Wine and Market shut its doors last month after nearly five years in business in Dallas, owner Michelle Bonds pointed to an unexpected reason for closure: GLP-1 weight loss drugs like ...
Fierce Healthcare23h
Hims & Hers' Super Bowl ad turns up the heat on GLP-1 battle
Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...
How The Democratization Of GLP-1s Might Redefine Standards And Status
It’s obvious these drugs are trimming waistlines across the nation; what may be less obvious is that they might also reshape ...